Yi Lin MD, PhD, discusses the impact of the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of relapsed or refractory multiple myeloma.
Yi Lin, MD, PhD
Advertisement
Yi Lin, MD, PhD, is a hematologist and oncologist with a clinical practice in lymphoma, multiple myeloma and cell therapy. Her current apointment is at the Mayo Clinic as a co-chair, Novel Immunotherapy Working Committee, International Myeloma Working Group, International Myeloma Foundation, member, Clinical Oncology Study Section, National Institutes of Health, and grant reviewer, Leukemia and Lymphoma Society.
Articles by Yi Lin, MD, PhD
Yi Lin MD, PhD, discusses long-term follow-up results from the CARTITUDE-1 study, which investigated ciltacabtagene autoleucel for the treatment of relapsed or refractory multiple myeloma.
Yi Lin MD, PhD explains how results from CARTITUDE-1 impact the treatment landscape for relapsed or refractory multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
